Risankizumab-rzaa (Skyrizi IV)

Provider Order Form rev. 1/23/2025



PATIENT INFORMATION	Referral Statu	Is: □ New Referral	☐ Updated Order	☐ Order Renewal	
Patient Name:		DOB:	Patient Phone	•	
Patient Address:		Pa	tient Email:		
Allergies:		☐ NKDA Weigl	nt (lbs/kg):	leight (in/cm):	
Sex: ☐ M / ☐ F Date of Last Infusion:	Next Due Da	ate: Pre	ferred Location:		
DIAGNOSIS (Please provide ICD-10 code in	space provided)				
☐ K50: Crohn's Disease	□ K51	: Ulcerative Colitis			
□ Other:	Description	:			
THERAPY ADMINISTRATION & DOSING ☑ Only IV induction dosing will be provided. Subcutaneous dosing WILL NOT be provided		LABORATORY ORDERS ☐ Bilirubin, LFTs at week 8 ☐ Other:			
For Crohn's Disease: ☐ Administer Risankizumab-rzaa (Skyrizi) 600mg IV over 1hour. Dilute in 100ml 0.9 NS or D5W For Ulcerative Colitis: ☐ Administer Risankizumab-rzaa (Skyrizi) 1200mg IV over 2 hours. Dilute in 250ml 0.9 NS or D5W		PRE-MEDICATION ORDERS ☐ Tylenol ☐ 500mg / ☐ 650mg PO ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☐ Solumedrol ☐ 40mg / ☐ 125mg IVP ☐ Other:			
FREQUENCY (Choose one) ☑ Induction: week 0, week 4, and week 8		NURSING ☑ Hold infusion and	notify provider for: nptoms of illness/activ	ve infection or recent	
ADDITIONAL ORDERS		☑ Provide nursing ca	Ts or bilirubin are per Nursing Proced ction Management Pro		
PROVIDER INFORMATION					
Preferred Contact Name:		Preferred Contact Email:			
Ordering Provider:		Provider NPI:			
Referring Practice Name: Practice Address:		Phone:	Fax:	Zin Codo:	
		,	State:	Zip Code:	
REQUIRED DOCUMENTATION CHECKL Required Documentation: Patient demos, cop treatment failures or contraindications with in Required Labs: TB, Hep B, CRP, ESR, LFTs and I	oy of front and back of nmunosuppressants, b	f primary and seconda	ary insurance, 2 most		
Provider Name (print)	Provider Signature			e	